The use of idiotype as a target for clinical immunotherapy of B cell malignancies.

S. B. Kim; L. W. Kwak

The use of idiotype as a target for clinical immunotherapy of B cell malignancies.

S. B. Kim, L. W. Kwak

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	289-295
Number of pages	7
Journal	Cancer chemotherapy and biological response modifiers
Volume	19
State	Published - 2001

ASJC Scopus subject areas

General Medicine

Cite this

@article{3b000b7b79ff4e9b86469edd6539d6ec,

title = "The use of idiotype as a target for clinical immunotherapy of B cell malignancies.",

author = "Kim, {S. B.} and Kwak, {L. W.}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2001",

language = "English (US)",

volume = "19",

pages = "289--295",

journal = "Cancer chemotherapy and biological response modifiers",

issn = "0921-4410",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - The use of idiotype as a target for clinical immunotherapy of B cell malignancies.

AU - Kim, S. B.

AU - Kwak, L. W.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2001

Y1 - 2001

UR - http://www.scopus.com/inward/record.url?scp=0035224888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035224888&partnerID=8YFLogxK

M3 - Review article

C2 - 11686018

AN - SCOPUS:0035224888

SN - 0921-4410

VL - 19

SP - 289

EP - 295

JO - Cancer chemotherapy and biological response modifiers

JF - Cancer chemotherapy and biological response modifiers

ER -

The use of idiotype as a target for clinical immunotherapy of B cell malignancies.

ASJC Scopus subject areas

Other files and links

Cite this